GARDNER, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. $(POCI)$, a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its second quarter fiscal year 2026 for the period ended December 31, 2025.
Q2 2026 Financial Highlights (3 Months Ended December 31, 2025):
-- Revenue was $7.4 million, a quarterly record, compared to $4.5 million in
the same quarter of the previous fiscal year, representing growth of
approximately 63%, and compared to $6.7 million in the most recent
sequential quarter.
-- Production revenue was $6.4 million, a quarterly record, compared to $3.1
million in the same quarter of the previous fiscal year, representing
growth of approximately 105%, and compared to $6.0 million in the most
recent sequential quarter.
-- Engineering revenue was $1.0 million compared to $1.4 million in the same
quarter of the previous fiscal year, a decrease of 29%, and compared to
$0.7 million in the most recent sequential quarter.
-- Gross margins were 2.8% compared to 23.6% in the same quarter of the
previous fiscal year.
-- Net loss for the quarter was $(1.8) million, compared to $(1.0) million
in the same quarter of the previous fiscal year.
-- Adjusted EBITDA was $(1.5) million for the quarter compared to $(0.6)
million in the same quarter of the previous fiscal year.
FY 2026 Financial Guidance (Year Ended June 30, 2026):
-- The Company is currently projecting revenue for fiscal year 2026 to be in
a range of $26 to $28 million, which represents 36% to 47% growth over
the Company's fiscal year 2025 revenue.
-- The Company is currently projecting fiscal year 2026 Adjusted EBITDA to
be approximately $(2.5) to ($3.0) million compared to $(3.7) million in
fiscal 2025.
"Our second quarter results demonstrate the continued strength of demand across our core production programs, with record revenue of $7.4 million driven by 105% year-over-year growth in Production," said Joe Forkey, CEO of Precision Optics. "Our aerospace program continues to perform at record shipment levels and is positioned for further expansion, while our single-use cystoscope program delivered its sixth consecutive record quarter of revenue. At the same time, our new single-use ophthalmic program is ramping and will be a key contributor to future growth.
"We are investing to build out required infrastructure of people and process in our production business. This is occurring while ramping programs and addressing associated inefficiencies. We are seeing tangible operational improvements that began to take hold toward the end of the quarter under new operations leadership. We expect margin performance to improve as we move through the second half of the fiscal year, Product Development bookings have increased for the third consecutive quarter to their highest level in over a year, and our Ross Optical division is entering the third quarter with its strongest backlog in more than three years. We believe the combination of sustained top-line growth, operational discipline, and strengthening bookings positions Precision Optics to transition from a period of investment and scaling to one of increasingly profitable growth," Forkey concluded.
The following table summarizes the second quarter and year-to-date (unaudited) results for the periods ending December 31, 2025, and 2024:
Three Months Six Months
Ended December 31 Ended December 31
----------------------- --------------------------
2025 2024 2025 2024
----------- ---------- ----------- -------------
Revenues $7,369,837 $4,526,907 $14,048,660 $8,723,960
Gross Profit 204,660 1,069,942 1,151,018 2,187,272
Stock
Compensation
Expenses 187,081 308,206 488,721 457,570
Other 1,759,908 1,671,757 3,999,881 3,886,664
----------- ---------- ----------- -----------
Total
Operating
Expenses 1,946,989 1,979,963 4,488,602 4,344,234
----------- ---------- ----------- -----------
Operating
Income
(Loss) (1,742,329) (910,021) (2,156,962) (2,156,962)
Net Income
(Loss) (1,780,791) (969,681) (3,417,821) (2,280,928)
Income (Loss)
per Share
$(0.23) $(0.15) $(0.44) $(0.36)
----------- ---------- ----------- -----------
Weighted
Average Common
Shares
Outstanding
Basic
and
Fully
Diluted 7,714,759 6,350,403 7,714,730 6,283,516
----------- ---------- ----------- -----------
Conference Call Details
Date and Time: Tuesday, February 17, 2026, at 5:00 p.m. ET.
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/Zo5aLdzPzmg.
Replay: A teleconference replay of the call will be available for seven days, at (855) 669-9658 or (412) 317-0088, replay access code 3100136. A webcast replay will be available at https://app.webinar.net/Zo5aLdzPzmg.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to the aforementioned items, Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation.
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, without limitation, the Company's projections for future revenue, gross margins and Adjusted EBITDA, expectations regarding margin improvement and operational performance, anticipated product and program expansion, and the Company's strategic outlook. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2026 16:30 ET (21:30 GMT)